Document is current
Any future updates will be listed below
-
Authors
Yau, Wai-Ying Wendy https://orcid.org/0000-0002-7597-7647
Kirn, Dylan R.
Rabin, Jennifer S. https://orcid.org/0000-0003-4754-2221
Properzi, Michael J.
Schultz, Aaron P.
Shirzadi, Zahra
Palmgren, Kailee
Matos, Paola
Maa, Courtney
Pruzin, Jeremy J.
Schultz, Stephanie A. https://orcid.org/0000-0001-8460-4415
Buckley, Rachel F. https://orcid.org/0000-0002-5356-5537
Rentz, Dorene M.
Johnson, Keith A.
Sperling, Reisa A. https://orcid.org/0000-0003-1535-6133
Chhatwal, Jasmeer P. https://orcid.org/0000-0002-7792-1698
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 12 August 2025
First Online: 3 November 2025
Competing interests
: The authors declare no competing interests relevant to the current study. Potential conflicts of interest outside the submitted work are included below. J.J.P. has served as a consultant for Eisai. K.A.J. has served as a consultant for Novartis, Merck and Janssen. R.A.S. has served as a consultant for AbbVie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Genentech, Ionis, Janssen, Oligomerix, Prothena, Roche and Vaxxinity over the past 3 years. K.A.J. and R.A.S. have received research funding from Eisai and Eli Lilly for public–private partnership clinical trials but do not have any personal financial relationship with the companies. J.P.C. has served as a consultant for ExpertConnect.
